Whole Genome vs Targeted Sequencing: Coverage Depth and Cost

Whole genome sequencing reads the entire genome of a sample, while targeted sequencing captures and reads only a chosen set of regions, from a few genes to a large panel. The choice between them is a strategy decision: whole genome maximizes discovery, while targeted sequencing concentrates read depth on the regions a project already knows it cares about.

The decision is driven by coverage depth and cost, but underneath those numbers sits the real question: is the goal to discover new variants or to validate known ones. This guide compares the two strategies and shows how to choose by the project's question rather than by the technology's headline capability.

The Two Strategies in One Comparison

Whole Genome Sequencing: Depth Spread Across Everything

Whole genome sequencing spreads the run's capacity across the entire genome, which means every region receives moderate coverage. The strength is that nothing is excluded: variants outside known genes, structural changes, and unexpected regions are all in the data. This is why whole genome sequencing is the discovery strategy, appropriate when the causal variant is unknown and the search cannot be limited to a panel.

The cost of that breadth is depth. At the same run capacity, whole genome coverage is far lower than a panel delivers on its targets, and low coverage means uncertain calls in difficult regions. For projects that need confident detection in specific genes, whole genome's moderate depth is a real limitation, not a detail to overlook.

Targeted Sequencing: Depth Concentrated on Chosen Regions

Targeted sequencing captures chosen regions before sequencing, so nearly all of the run's capacity lands on the targets. This produces deep coverage, often orders of magnitude above whole genome, which translates into confident variant calls, including low-frequency variants that moderate coverage would miss. This is why targeted panels are the validation and monitoring strategy: the regions are known, and the goal is sensitivity within them.

The limitation is structural: nothing outside the panel is read. A variant just beyond the captured region, or a new gene implicated after the panel was designed, is invisible. Panels are commitments to a hypothesis about where the answer lives, and that commitment is exactly what makes them cheaper and deeper.

Coverage Depth as the Deciding Variable

Depth is the number of times each base is read, and it determines how confidently variants can be called. Whole genome projects commonly target moderate depth, enough for germline variant discovery, while targeted panels reach much higher depth, enabling somatic and low-frequency variant detection. The same sequencing capacity buys either breadth at shallow depth or narrowness at deep depth, never both at once.

This trade-off should be stated in the project's terms: what minimum depth does the detection goal require, and which regions must meet it. A project that needs deep coverage of twenty genes is a panel project; a project that needs any variant anywhere is a whole genome project. Depth requirements are derived from the question, not from the technology.

Cost and the Validation-Discovery Split

Per-sample cost follows the same logic. Whole genome costs more per sample because each sample consumes a large share of the run's capacity; a panel costs less per sample because many samples share the run while only the captured regions are read. This is why programs that validate the same genes across thousands of samples use panels, while exploratory studies of new disease mechanisms use whole genome sequencing on fewer samples.

The two strategies also fit a natural sequence within a project. Whole genome discovery on a cohort can identify the regions that matter, and a panel built from those findings then validates them at scale and depth. Treating the strategies as rivals misses the workflow in which discovery feeds panel design, and panels return the depth that confirms what discovery found.

Documenting the Strategy With the Data

Sequencing strategy is part of the reproducible context of every variant call. A result file should record which regions were sequenced, at what depth, and with which capture design, so a reviewer knows what the data can and cannot support. A panel result carries its panel definition; a whole genome result carries its coverage distribution. When this context is attached to the analysis and the experiment record, results become interpretable by others. For teams that want sequencing context and experiment documentation connected, Zettalab links structured records with team file collaboration, keeping the strategy, the data, and the conclusion in one traceable workspace.

FAQ

What is the difference between whole genome and targeted sequencing?

Whole genome sequencing reads the entire genome at moderate depth, maximizing discovery of variants anywhere. Targeted sequencing captures chosen regions and reads them deeply, maximizing sensitivity within the panel. The difference is breadth versus depth: whole genome sees everything but less confidently per region, while targeted panels see only their regions but with high confidence.

When should I choose a targeted sequencing panel?

Choose a panel when the regions of interest are already known and the goal is sensitive detection within them, such as validating known disease genes across many samples or monitoring defined variants. Panels deliver much higher depth per dollar than whole genome, so they suit high-volume validation work. The trade-off is that variants outside the panel are invisible.

How much coverage does whole genome sequencing need?

The required depth depends on the detection goal. Germline variant discovery typically uses moderate depth, while somatic or low-frequency variant detection needs more. The number should be derived from the sensitivity the project requires in its regions of interest, not from a default. If the required depth cannot be reached genome-wide within budget, targeted sequencing is the stronger strategy.

Is targeted sequencing always cheaper than whole genome?

Per sample, yes in most cases, because each sample consumes less of the run's capacity and many samples share the capture and sequencing cost. The comparison assumes the panel already exists; designing a panel adds upfront cost. Over large sample counts, the panel's per-sample advantage dominates, which is why high-volume validation programs use panels while small exploratory cohorts use whole genome sequencing.

Conclusion

Whole genome and targeted sequencing represent a breadth-versus-depth choice: whole genome for discovery of unknown variants, targeted panels for deep validation of known regions. Deriving depth requirements from the detection goal, and letting discovery feed panel design, makes the strategy decision follow the science. To connect sequencing context with lab documentation, explore Zettalab's cloud-based R&D lab platform.